TARGETING a receptor responsible for our sense of touch and temperature, which researchers have now found to be present in our colon, could provide a new avenue for treating chronic pain associated with gastrointestinal disorders such as irritable bowel syndrome.
A team examining the colon, led by Professor Hongzhen Hu at Washington University in St Louis and Professor Nick Spencer at Flinders University, identified the presence of Piezo2, the subject of the 2021 Nobel Prize in Physiology or Medicine, now known to be responsible for sensing light touch on our skin.
"In discovering that this receptor is also in our gut, there's the potential that selectively targeting these channels could be used for long-term silencing of pain sensations from internal organs, without the need for frequent consumption of opiate pain medications," said Professor Spencer, a Matthew Flinders Professor in the College of Medicine and Public Health.
"Chronic pain from internal organs, such as the gut or bladder, is notoriously difficult to treat.
"Opiates, including morphine and their derivates have been commonly used to treat a variety of types of pain but visceral pain doesn't respond well to the treatment and the drugs are highly addictive with a multitude of side effects."
The authors said the availability of selective pain medications for the gut has been hindered by a lack of understanding about how sensory nerves communicate pain sensations from the gut to the brain.
"It was previously known that many different ion channels are located on the 'pain-sensing' neurons that communicate from the gut to the brain, but our study, published in the journal Neuron, has now identified the major ion channel in the colon that responds to mechanical stimulation leading to the sensation of pain," said Professor Spencer.
"Furthermore, we have discovered that the major ion channel that responds to this mechanical pain is a member of the Piezo ion channel, specifically Piezo2.
"We can target these channels to silence pain sensations," he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jan 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jan 23
